Please see this new paper, which includes updated data on what patients pay for Xpert MTB/RIF testing in the private health sector in highly privatized health markets. It is an update of a previous study (Puri et al. Lancet GH 2016).
The results show that Xpert continues to be expensive for patients in the private health sector, even in the highest TB burden countries. We need to work harder to ensure that new TB tools are affordable and accessible to patients in the private health sector in LMICs. The paper provides several suggestions.